Phaseline

Companies › Caribou Biosciences

Caribou Biosciences: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CB-010
CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy
CD19Phase 1Lymphoma, Non-HodgkinDec 2026
Lornoxicam (CB-011)
Cyclooxygenase inhibitor
PTGS2, PTGS1Phase 1Relapsed/Refractory Multiple MyelomaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04637763CB-010Phase 1Lymphoma, Non-HodgkinOncologyDec 2026
NCT05722418Lornoxicam (CB-011)Phase 1Relapsed/Refractory Multiple MyelomaOncologyDec 2027

From the company's SEC filings

Cash and short-term investments of $95m on 2026-09-30; operating cash outflow about $97m a year; runway about 12 months at that burn, to Sep 2027

Press releases filed as 8-K in the last year:

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CD19 (1) PTGS2 (1) PTGS1 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.